• Daniel G Tanenbaum, Zachary S Buchwald, Jaymin Jhaveri, Eduard Schreibmann, Jeffrey M Switchenko, Roshan S Prabhu, Mudit Chowdhary, Mustafa Abugideiri, Neil T Pfister, Bree Eaton, Shannon E Kahn, Jeffrey J Olson, Hui-Kuo G Shu, Ian R Crocker, Walter J Curran, and Kirtesh R Patel.
• Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
• Pract Radiat Oncol. 2020 Jan 1; 10 (1): 36-43.

PurposeStereotactic radiosurgery (SRS) is increasingly used in the management of patients with resected brain metastases (rBMs). A significant complication of this therapy can be radiation necrosis (RN). Despite radiation therapy dose de-escalation and the delivery of several rather than a single dose fraction, rates of RN after SRS for rBMs remain high. We evaluated the dosimetric parameters associated with radiographic RN for rBMs.Methods And MaterialsFrom 2008 to 2016, 55 rBMs at a single institution that were treated postoperatively with 5-fraction linear accelerator-based SRS (25-35 Gy) with minimum 3 months follow-up were evaluated. For each lesion, variables recorded included radiation therapy dose to normal brain, location and magnitude of hotspots, clinical target volume (CTV), and margin size. Hotspot location was stratified as within the tumor bed alone (CTV) or within the planning target volume (PTV) expansion margin volume (PTV minus CTV). Cumulative incidence with competing risks was used to estimate rates of RN and local recurrence. Optimal cut-points predicting for RN for hotspot magnitude based on location were identified via maximization of the log-rank test statistic.ResultsMedian age for all patients was 58.5 years. For all targets, the median CTV was 17.53 cm3, the median expansion margin to PTV was 2 mm, and the median max hotspot was 111%. At 1 year, cumulative incidence of radiographic RN was 18.2%. Univariate analysis showed that max hotspots with a hazard ratio of 3.28 (P = .045), hotspots within the PTV expansion margin with relative magnitudes of 105%, 110%, and 111%, and an absolute dose of 33.5 Gy predicted for RN (P = .029, P = .04, P = .038, and P = .0488, respectively), but hotspots within the CTV did not.ConclusionsTo our knowledge, this is the first study that investigated dosimetric factors that predict for RN after 5-fraction hypofractionated SRS for rBM. Hotspot location and magnitude appear important for predicting RN risk, thus these parameters should be carefully considered during treatment planning.Copyright © 2019 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

37 keywords...

hide…